ES2126122T3 - Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio. - Google Patents

Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio.

Info

Publication number
ES2126122T3
ES2126122T3 ES94918734T ES94918734T ES2126122T3 ES 2126122 T3 ES2126122 T3 ES 2126122T3 ES 94918734 T ES94918734 T ES 94918734T ES 94918734 T ES94918734 T ES 94918734T ES 2126122 T3 ES2126122 T3 ES 2126122T3
Authority
ES
Spain
Prior art keywords
therapy
disulphes
cardio
nitrate
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918734T
Other languages
English (en)
Inventor
Klaus Sandrock
Martin Feelisch
Hilmar Bokens
Jochen Lehmann
Claus Meese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanol Schwarz GmbH
UCB Pharma GmbH
Original Assignee
Sanol Schwarz GmbH
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Schwarz GmbH, Schwarz Pharma AG filed Critical Sanol Schwarz GmbH
Application granted granted Critical
Publication of ES2126122T3 publication Critical patent/ES2126122T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS NITRATOS, CONTENIENDO GRUPOS DISULFURO, POR EJEMPLO DE LA FORMULA (I) EN DONDE R, R'', R{SUP, 1}, R{SUP, 1''}, R{SUP, 2}, R{SUP, 2''}, R{SUB, 3}, R {SUB, 3''}, R{SUP, 4}, R{SUP, 4''}, R{SUB, 5}, R{SUP, 5''}, M,M'', N, N'', O, O'', P, P'', Q, Q'' SE DEFINEN COMO EN LA REIVINDICACION 1, Y PROCESO PARA SU ELABORACION. LOS COMPUESTOS PUEDEN SER UTILIZADOS PARA TERAPIAS DE ENFERMEDADES DEL SISTEMA CARDIOVASCULAR.
ES94918734T 1993-06-26 1994-06-24 Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio. Expired - Lifetime ES2126122T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4321306A DE4321306A1 (de) 1993-06-26 1993-06-26 Disulfide

Publications (1)

Publication Number Publication Date
ES2126122T3 true ES2126122T3 (es) 1999-03-16

Family

ID=6491310

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918734T Expired - Lifetime ES2126122T3 (es) 1993-06-26 1994-06-24 Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio.

Country Status (12)

Country Link
US (1) US5661129A (es)
EP (1) EP0705244B1 (es)
JP (1) JPH08511777A (es)
KR (1) KR100265181B1 (es)
CN (1) CN1045594C (es)
AT (1) ATE172963T1 (es)
CA (1) CA2165992C (es)
DE (2) DE4321306A1 (es)
DK (1) DK0705244T3 (es)
ES (1) ES2126122T3 (es)
HK (1) HK1013283A1 (es)
WO (1) WO1995000477A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115661B1 (en) 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US5807847A (en) * 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US6284790B1 (en) * 2000-06-15 2001-09-04 Sachin Gupte Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
DE60233140D1 (de) 2001-05-02 2009-09-10 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
US6696592B2 (en) * 2001-05-22 2004-02-24 Nicox-S.A. Methods of making 21-[4′-(nitrooxyalkyl)benzoate] corticosteroid derivatives and intermediates useful in the synthesis thereof
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP1414432A4 (en) * 2001-08-10 2008-01-09 Nitromed Inc APPLICATION METHOD FOR NEW SULFURIC ORGANIC NITRATE COMPOUNDS
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
AU2004266705A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP1667643A4 (en) * 2003-08-28 2008-03-05 Nitromed Inc NITROSIS AND NITROSYL CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
AU2005207037A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
EP1814535A4 (en) * 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
EP1846380A4 (en) * 2005-01-21 2010-02-17 Nicox Sa HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME
US20090042819A1 (en) * 2005-02-16 2009-02-12 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
CA2597463A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
JP2008535858A (ja) * 2005-04-07 2008-09-04 ニトロメッド インコーポレーティッド 心不全における遺伝リスク、すなわちｎｏｓ３の遺伝子変異の影響の評価方法
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
EP1883614A4 (en) * 2005-05-23 2010-04-14 Nicox Sa ORGANIC NITRIC OXIDES IMPROVING SALTS FROM NON-SUBSTITUTE INFLAMMATORY COMPOUNDS AND COMPOSITIONS AND USES THEREOF
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
CA2624930A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US20090053328A1 (en) * 2005-12-20 2009-02-26 Nitromed, Inc. Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
US8445002B2 (en) 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
EP3266463B1 (en) 2009-06-09 2023-12-13 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US9428453B2 (en) 2013-01-02 2016-08-30 Rutgers, The State University Of New Jersey Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
EP3464336B1 (en) 2016-06-01 2022-03-16 Athira Pharma, Inc. Compounds
WO2021119475A1 (en) * 2019-12-13 2021-06-17 Rutgers, The State University Of New Jersey Cystine diamide analogs for cystinuria
WO2023107470A1 (en) * 2021-12-06 2023-06-15 Pretzel Therapeutics, Inc. Lonp1 inhibitors, uses and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428061A (en) * 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
JP2628756B2 (ja) * 1988-09-15 1997-07-09 シュバルツファルマ アクチェンゲゼルシャフト 新規有機ニトレート及びそれらの製造方法
DE4011505C2 (de) * 1990-04-10 1995-01-12 Sanol Arznei Schwarz Gmbh Nitratoalkancarbonsäure-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof

Also Published As

Publication number Publication date
US5661129A (en) 1997-08-26
EP0705244A1 (de) 1996-04-10
CN1126466A (zh) 1996-07-10
HK1013283A1 (en) 1999-08-20
JPH08511777A (ja) 1996-12-10
DE59407237D1 (de) 1998-12-10
DE4321306A1 (de) 1995-01-05
CA2165992C (en) 2000-08-22
DK0705244T3 (da) 1999-07-19
KR960702831A (ko) 1996-05-23
ATE172963T1 (de) 1998-11-15
KR100265181B1 (ko) 2000-09-15
EP0705244B1 (de) 1998-11-04
CN1045594C (zh) 1999-10-13
WO1995000477A1 (de) 1995-01-05

Similar Documents

Publication Publication Date Title
ES2126122T3 (es) Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio.
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
ES2102367T3 (es) Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
FI961054A0 (fi) Menetelmä 9-(2-hydroksi)etoksimetyyliguaniinin valmistamiseksi
DK229984D0 (da) 4-oxothiazolidin-2-yliden-acetamid-derivater
IL88726A0 (en) Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
ATE112276T1 (de) Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE243683T1 (de) Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln
IL115004A0 (en) Use of substituted 6-amino-4h-pyrans as medicaments, certain novel such compounds and their preparation
BR9714184A (pt) Utilização de bonzoillquil-1,2,3,6-tetraidropiridinas
NO974687D0 (no) Kondenserte <beta>-carboliner
IT1269740B (it) Derivati di combretastatine ad attivita' anti-tumorale e procedimento per la loro preparazione
ATE94558T1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 705244

Country of ref document: ES